<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00108875</url>
  </required_header>
  <id_info>
    <org_study_id>SuMo-Sec-01</org_study_id>
    <secondary_id>PEI 0899/01</secondary_id>
    <secondary_id>IRB 07/03</secondary_id>
    <nct_id>NCT00108875</nct_id>
  </id_info>
  <brief_title>Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer</brief_title>
  <official_title>Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Julius-Maximilians University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Julius-Maximilians University</source>
  <brief_summary>
    <textblock>
      This study evaluates the safety, the immunological response and the clinical outcome of a
      vaccination with survivin peptides for patients with advanced melanoma, pancreatic, colon and
      cervical carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As prognosis of advanced melanoma, pancreatic, colon and cervical cancer remains gloomy, new
      therapeutic modalities have to be developed to improve the patient´s clinical outcome.
      Immunotherapy, which targets tumor associated antigens of tumor cells or tumor stroma, is
      currently an intensively investigated, novel therapeutic option. As survivin is expressed
      both by neoplastic cells as well as by endothelial cells of the tumor vasculature, this
      antigen is an intriguing target molecule. Spontaneous cytotoxic T-cell responses against
      different survivin epitopes in cancer patients underline the relevance of survivin-directed
      immunological trials. This study is comprised of a peptide vaccine with HLA-A1, -A2 and -B35
      restricted survivin epitopes in Montanide ISA-51 for patients with stage IV melanoma,
      advanced pancreatic, colon and cervical carcinoma. The vaccine is applicated as a deep
      subcutaneous injection. Vaccination is administered for the first 2 months weekly, afterwards
      every 4 weeks. Standard staging examinations are performed every three months. Clinical,
      laboratory and immunological monitoring is done every month.Diagnostic leucapheresis is
      performed before first vaccination and afterwards every 2 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2003</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
  </secondary_outcome>
  <enrollment>70</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Survivin peptide vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced melanoma, pancreatic, colon and cervical cancer

          -  At least 1 prior postoperative conventional therapy (chemotherapy, radiation,
             immunotherapy)

          -  HLA-A1, -A2, -B35

          -  More than 4 weeks since last chemo-, immune- or radiotherapy

          -  ECOG-PS (Eastern Cooperative Oncology Group- Performance Status) of 0-1

          -  Sufficient renal, hepatic and bone marrow function: thrombocytes &gt; 75.000/ul; hb &gt; 9
             g/dl; leucocytes &gt; 2.500/ul; creatinine &lt; 2 mg/dl; GOT/GPT &lt; twice the normal value

          -  negative for HIV and Hbs

          -  Older than 18 years

          -  Informed consent

        Exclusion Criteria:

          -  Acute/chronic infections

          -  Positive for HIV, Hbs

          -  Autoimmune disorders

          -  Pregnancy, breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen C Becker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, University of Wuerzburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juergen C Becker, MD, PhD</last_name>
    <phone>+49-931-201-26396</phone>
    <email>becker_jc@klinik.uni-wuerzburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion B Wobser</last_name>
    <phone>+49-931-201-26722</phone>
    <email>wobser_m@klinik.uni-wuerzburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Julius-Maximilians-University of Wuerzburg, Germany, Department of Dermatology</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juergen C Becker, MD, PhD</last_name>
      <phone>+49-931-201-26396</phone>
      <email>becker_jc@klinik.uni-wuerzburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Marion B Wobser</last_name>
      <phone>+49-931-201-26722</phone>
      <email>wobser_m@klinik.uni-wuerzburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Juergen C Becker, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003 Jul;9(7):2683-92.</citation>
    <PMID>12855648</PMID>
  </reference>
  <reference>
    <citation>Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LØ, Rath JC, Böck M, Bröcker EB, Straten PT, Kämpgen E, Becker JC. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine. 2005 Jan 4;23(7):884-9.</citation>
    <PMID>15603888</PMID>
  </reference>
  <reference>
    <citation>Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001 Aug 15;61(16):5964-8.</citation>
    <PMID>11507035</PMID>
  </reference>
  <reference>
    <citation>Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001 Feb 1;61(3):869-72.</citation>
    <PMID>11221872</PMID>
  </reference>
  <reference>
    <citation>Kim HS, Shiraki K, Park SH. Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix. Anticancer Res. 2002 Mar-Apr;22(2A):805-8.</citation>
    <PMID>12014654</PMID>
  </reference>
  <reference>
    <citation>Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004 Mar 1;108(6):937-41.</citation>
    <PMID>14712500</PMID>
  </reference>
  <reference>
    <citation>Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004 Feb;3(2):173-9. Epub 2004 Feb 1.</citation>
    <PMID>14726703</PMID>
  </reference>
  <verification_date>June 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2005</study_first_submitted>
  <study_first_submitted_qc>April 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2005</study_first_posted>
  <last_update_submitted>July 27, 2006</last_update_submitted>
  <last_update_submitted_qc>July 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2006</last_update_posted>
  <keyword>Peptide vaccine therapy</keyword>
  <keyword>Survivin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

